Implementation of a vaccination clinic for adult solid organ transplant candidates : A single-center experience
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Vaccination is an evidence-based strategy to prevent or reduce the severity of infectious diseases (ID). Here, we aimed to describe the experience of implementing a vaccination clinic specifically targeting liver, heart, lung, and combined dual organ transplantation at a single transplantation center in Denmark. In this cohort of 242 solid organ transplant (SOT) candidates, we investigated seroprotection and the proportion of recommended vaccinations documented before transplantation. Furthermore, we registered completed vaccinations after ID consultations. The median age in our cohort was 53 years (IQR, 42-60), 60% were males (n = 135), and liver transplants (n = 138; 57%) were the most frequently planned organ transplants. Before the consultation to the vaccination clinic, influenza and pneumococcal vaccines had the highest proportion of documented vaccination (58% and 37%, respectively). Serological protection was more frequently observed for measles, mumps, or rubella (MMR, approximately 90% for each), while only 30% (n = 72) of SOT candidates showed seroprotection against pneumococcal disease. All SOT candidates required at least one of the recommended vaccines, and over 90% required three or more. At least 10% of patients in our cohort needed a live attenuated vaccine for either MMR or yellow fever. The most frequently administered vaccine was the tetanus-diphtheria-acelullar pertussis (Tdap) booster (n = 217; 90%), influenza vaccination was either administered (n = 16; 7%) or recommended (n = 226; 93%), PCV13 was administered (n = 155; 64%) or recommended (n = 27; 11%), and PPSV23 was either administered (n = 18; 7.4%) or recommended (n = 140; 58%). All SOT candidates adhered completely to their vaccination schedules. Based on our findings, we recommend prioritizing vaccination before transplantation by providing ID consultations for SOT candidates.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Vaccine - 41(2023), 45 vom: 26. Okt., Seite 6637-6644 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Harboe, Zitta Barrella [VerfasserIn] |
---|
Links: |
---|
Themen: |
Journal Article |
---|
Anmerkungen: |
Date Completed 23.10.2023 Date Revised 24.10.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.vaccine.2023.09.036 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM362715408 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM362715408 | ||
003 | DE-627 | ||
005 | 20231226091818.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2023.09.036 |2 doi | |
028 | 5 | 2 | |a pubmed24n1208.xml |
035 | |a (DE-627)NLM362715408 | ||
035 | |a (NLM)37775467 | ||
035 | |a (PII)S0264-410X(23)01106-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Harboe, Zitta Barrella |e verfasserin |4 aut | |
245 | 1 | 0 | |a Implementation of a vaccination clinic for adult solid organ transplant candidates |b A single-center experience |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.10.2023 | ||
500 | |a Date Revised 24.10.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
520 | |a Vaccination is an evidence-based strategy to prevent or reduce the severity of infectious diseases (ID). Here, we aimed to describe the experience of implementing a vaccination clinic specifically targeting liver, heart, lung, and combined dual organ transplantation at a single transplantation center in Denmark. In this cohort of 242 solid organ transplant (SOT) candidates, we investigated seroprotection and the proportion of recommended vaccinations documented before transplantation. Furthermore, we registered completed vaccinations after ID consultations. The median age in our cohort was 53 years (IQR, 42-60), 60% were males (n = 135), and liver transplants (n = 138; 57%) were the most frequently planned organ transplants. Before the consultation to the vaccination clinic, influenza and pneumococcal vaccines had the highest proportion of documented vaccination (58% and 37%, respectively). Serological protection was more frequently observed for measles, mumps, or rubella (MMR, approximately 90% for each), while only 30% (n = 72) of SOT candidates showed seroprotection against pneumococcal disease. All SOT candidates required at least one of the recommended vaccines, and over 90% required three or more. At least 10% of patients in our cohort needed a live attenuated vaccine for either MMR or yellow fever. The most frequently administered vaccine was the tetanus-diphtheria-acelullar pertussis (Tdap) booster (n = 217; 90%), influenza vaccination was either administered (n = 16; 7%) or recommended (n = 226; 93%), PCV13 was administered (n = 155; 64%) or recommended (n = 27; 11%), and PPSV23 was either administered (n = 18; 7.4%) or recommended (n = 140; 58%). All SOT candidates adhered completely to their vaccination schedules. Based on our findings, we recommend prioritizing vaccination before transplantation by providing ID consultations for SOT candidates | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Vaccines, Attenuated |2 NLM | |
700 | 1 | |a Hald, Annemette |e verfasserin |4 aut | |
700 | 1 | |a Ekenberg, Christina |e verfasserin |4 aut | |
700 | 1 | |a Ete Wareham, Neval |e verfasserin |4 aut | |
700 | 1 | |a Fogt Lundbo, Lene |e verfasserin |4 aut | |
700 | 1 | |a Holler, Jon Gitz |e verfasserin |4 aut | |
700 | 1 | |a Qvist, Tavs |e verfasserin |4 aut | |
700 | 1 | |a Rask Hamm, Sebastian |e verfasserin |4 aut | |
700 | 1 | |a Bjerrum, Stephanie |e verfasserin |4 aut | |
700 | 1 | |a Rezahosseini, Omid |e verfasserin |4 aut | |
700 | 1 | |a Suno Krohn, Paul |e verfasserin |4 aut | |
700 | 1 | |a Gustafsson, Finn |e verfasserin |4 aut | |
700 | 1 | |a Perch, Michael |e verfasserin |4 aut | |
700 | 1 | |a Rasmussen, Allan |e verfasserin |4 aut | |
700 | 1 | |a Dam Nielsen, Susanne |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 41(2023), 45 vom: 26. Okt., Seite 6637-6644 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2023 |g number:45 |g day:26 |g month:10 |g pages:6637-6644 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2023.09.036 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2023 |e 45 |b 26 |c 10 |h 6637-6644 |